Subjects who have a positive serum human chorionic gonadotropin (hCG), are pregnant or lactating are ineligible Pregnant or nursing (lactating) women, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test (> mIU/mL); pregnancy is ruled out by a beta hCG test completed if necessary with an ultrasound Females who are pregnant (beta-human chorionic gonadotropin positive [beta-HCG+]) or breast-feeding Female subjects who are nursing or pregnant (positive serum or urine beta-human chorionic gonadotropin [B-hCG] pregnancy test) DONOR: females who are pregnant (positive serum beta-human chorionic gonadotropin [B-HCG]) or uninterruptible breastfeeding Female subjects who are nursing or pregnant (positive serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test) at screening or pre-dose on day Performed within business days of treatment initiation with the exception of beta-human chorionic gonadotropin (HCG) ( hours), if applicable: Absolute neutrophil count (ANC) >= /uL. Pregnant or breastfeeding women who do not consent to stop breast-feeding while on study treatment and for days after the use of the investigational vaccine where pregnancy is confirmed by a positive, rising human chorionic gonadotropin (hCG) laboratory test Female patients who are pregnant (positive beta-HCG) or breastfeeding. Female patients who are pregnant confirmed by beta human chorionic gonadotropin (bHCG) laboratory (lab) test Female subjects who are nursing or pregnant (positive serum or urine Beta-human chorionic gonadotropin [B-hCG] pregnancy test) Normal beta-human chorionic gonadotropin (HCG) (per the local laboratory assay) within days of RPLND Subject is pregnant or nursing; serum or urine beta-human chorionic gonadotropin (HCG) must be checked in all non-postmenopausal patients or patients of childbearing potential WOCBP who have a positive beta-human chorionic gonadotropin (hCG) test or are breastfeeding Female patients who are diagnosed as pregnant by beta human chorionic gonadotropin (hCG) testing (per institutional practice) or breast-feeding Female patients who are pregnant (positive beta-human chorionic gonadotropin [B-HCG]) or breastfeeding Pregnant or nursing (to be confirmed with quantitative human chorionic gonadotropin [HCG] testing) Pregnant or need to breast feed during the study period (negative beta-human chorionic gonadotropin [HCG] test required), or unable to maintain use of contraception while on study and for weeks after the last dose of nivolumab DONOR:\r\n* Donors will be excluded if they are an identical twin of the recipient\r\n* Females who are pregnant (positive serum beta human chorionic gonadotropin beta [? HCG]) or uninterruptible breastfeeding\r\n* HIV seropositive\r\n* Donors receiving experimental therapy or investigational agents unless approved by the protocol chair Negative serum beta-human chorionic gonadotropin (HCG) Subject is pregnant, has a positive serum human chorionic gonadotropin (hCG) or is lactating Subjects who are pregnant, have a positive serum human chorionic gonadotropin (hCG) or are lactating Female patients of childbearing age are excluded if they are pregnant as determined with a serum beta HCG no greater than days prior to study registration, or breast-feeding. (The exclusion is made because gadolinium may be teratogenic in pregnancy). Beta human chorionic gonadotropin (beta HCG) negative Female patients who are pregnant (positive beta-human chorionic gonadotropin [b-HCG]) or breast feeding. Pregnant women are excluded from this study, where pregnancy is confirmed by a positive serum beta-human chorionic gonadotropin (hCG) laboratory test; breast-feeding should be discontinued Female patients who are pregnant (positive b-human chorionic gonadotropin [HCG]) or breastfeeding Female patients who are pregnant (positive beta-human chorionic gonadotropin [HCG]) or breastfeeding will be excluded from study entry; sexually active men and women must use contraceptive techniques during and for weeks following completion of maintenance therapy The patient is pregnant (confirmed by serum beta human chorionic gonadotropin [b-HCG], if applicable) or is breastfeeding Pregnant (i.e., positive beta-human chorionic gonadotropin test) or lactating Is pregnant (confirmed by beta human chorionic gonadotrophin [?-HCG]) or lactating. Patient is pregnant (confirmed by serum beta- b-human chorionic gonadotropin [HCG] if applicable) or is breastfeeding HAPLO-IDENTICAL DONOR: Pregnancy (positive serum or urine beta-human chorionic gonadotropin [HCG]) or breastfeeding; women of childbearing age must avoid becoming pregnant while on the study DONOR: Pregnancy (positive serum or urine beta-human chorionic gonadotropin [b-HCG]) or breastfeeding; women of childbearing age must avoid becoming pregnant while on the study Pregnant women with a positive (blood beta-human chorionic gonadotropin [B-HCG]) pregnancy test are excluded from this study Females must not be pregnant (negative human chorionic gonadotropin test within hours prior to receiving the first dose of study medication) or breastfeeding Pregnant females as determined by positive human chorionic gonadotropin (hCG) test at screening or prior to dosing. Female subjects must not be pregnant as documented by a negative beta-human chorionic gonadotropin (beta-hCG) test with a minimum sensitivity IU/L or equivalent unit of beta-hCG at Screening and Baseline, or breastfeeding. Pregnancy (positive serum beta human chorionic gonadotropin [b-HCG]) or breastfeeding Pregnant or breast-feeding; pre-menopausal patients must have a negative serum human chorionic gonadotropin (HCG) within days of enrollment Pregnant (i.e., positive beta-human chorionic gonadotropin [HCG]) or breast feeding Women who are pregnant or post-partum (within months of delivery); patients are deemed not pregnant by virtue of urine pregnancy test (UPT), transvaginal ultrasound, beta human chorionic gonadotropin (HCG), or best judgement of the investigator; pregnancy testing is not required per protocol to determine study eligibility; women who become pregnant on the ISDO arm via reproductive technology can remain on study; however, data collection will be suspended during pregnancy and months post-partum Pregnant or need to breast feed during the study period (negative urine beta-human chorionic gonadotropin [HCG] test required), or unable to maintain use of contraception while on study and for month after the last dose of AED Women who are pregnant; patients are deemed not pregnant by virtue of urine pregnancy test (UPT), transvaginal ultrasound, beta human chorionic gonadotropin (HCG), or best judgement of the investigator, pregnancy testing is not required per protocol to determine study eligibility Female patient who is pregnant or lactating (the possibility of pregnancy has to be excluded by negative serum or urine beta-human chorionic gonadotropin [?-HCG] results, obtained within hours before the perflutren lipid administration, or on the basis of patient history, e.g.: tubal ligation, hysterectomy or a minimum of year without menses) Any woman who is pregnant or has reason to believe she is pregnant or any woman who is lactating (the possibility of pregnancy has to be excluded by negative urine beta-human chorionic gonadotropin [beta-HCG] results, obtained within hours before the perflutren lipid administration, or on the basis of patient history, e.g.: tubal ligation, hysterectomy or a minimum of year without menses) Pregnant women and women who are breast feeding will be excluded from this study; (the Vanderbilt University Medical Center radiology MRI Procedure Screening Form will be used to identify and exclude subjects who are pregnant or breastfeeding; a urine pregnancy test/or serum beta human chorionic gonadotropin [HCG] will also be performed for each pre-menopausal subject) The participant, if female, is pregnant (confirmed by serum or urine beta-human chorionic gonadotropin [?-HCG] pregnancy test) or breastfeeding The participant, if female, is pregnant (confirmed by serum or urine beta-human chorionic gonadotropin [?-HCG] pregnancy test) or breastfeeding